**TTD: Board Resolution**

On March 4, 2024, Tam Duc Cardiology hospital joint stock company announced Resolution No. VI.24/NQ-HDQT as follows:

Article I. Approve the results of professional activities in 2023:

In 2023, Tam Duc achieved the goal of treatment quality and patient satisfaction with better operating capacity compared to 2022.

In 2023, medical visits increased by 3% compared to 2022. Inpatient care increased by 6% compared to 2022. Surgical activity remained stable in 2023, with 442 cases performed, similar to the number in 2022 (442/443), exceeding the target of 400 cases. Interventional cardiology procedures increased by 7.7% compared to 2022 (1,722/1,599). Electrophysiology procedures increased by 4.5% compared to 2022 (416/398). New techniques had been successfully developed, including 3D mapping ablation for supraventricular tachycardia reducing X-ray exposure time, and His bundle pacing reducing the risk of long-term heart failure. Paraclinical activities in 2023 decreased by 5% compared to 2022 (969,659/1,019,186), but were still higher than the pre-pandemic years.

The Board of Directors VI.24 unanimously approved the results of professional activities in 2023.

Article II. Approve the financial result of Tam Duc in 2023:

|  |  |  |
| --- | --- | --- |
|  | Plan for 2023 | Results in 2023 |
| Revenue: | VND 680 billion | VND 749.67 billion |
| Profit before tax: | VND 82 billion | VND 93.80 billion |
| Profit after tax: | VND 74 billion | VND 83.07 billion |

In 2023, Tam Duc recovered from the Covid-19 pandemic, operating capacity was better than in 2022. Therefore, the financial results in 2023 exceeded the plan, revenue increased by 10.2%.

The rate of profit before tax/Total revenue in 2023 was 12.51%, lower than in 2022 (14.28%).

Labor costs increased in the emergency, intensive care, and high-tech treatment areas.

Depreciation and allocation costs increased compared to 2022 due to large equipment investments in 2022 and 2023.

Selling expense was equivalent to 2022. The selling expense in 2023 was 2.37%/total cost compared to 2.35% in 2022.

General and administrative expense was equivalent to 2022. The general and administrative expense in 2023 was 9.69%/total cost compared to 9.62% in 2022.

The Board of Directors of VI.24 unanimously approved the financial performance results in 2023.

Article III. Regarding dividends in 2023:

The General Meeting of Shareholders 2023 approved the dividend payment plan of 30% in 2023. Based on business performance results in 2023, the Board of Directors will submit to the General Metting of Shareholders 2024 to approve the dividend rate of 33%/par value in 2023.

The Board of Directors VI.24 unanimously approved to submit to the General Meeting of Shareholders 2024 to approve the dividend rate of 33%/par value in 2023.

Article IV. Bonus for Lunar New Year 2025

The Board of Directors VI.24 unanimously approved to make monthly deductions to ensure the Lunar New Year bonus in 2025 is equivalent to the Lunar New Year bonus in 2024.

Article V: Welfare and Bonus Fund in 2024:

To ensure the completion of the financial plan and stabilize employee morale, the decision to allocate the Welfare and Reward Fund for 2024 is VND 3.5 billion instead of VND 2 billion in 2023.

The Board of Directors of VI.24 unanimously approved the proposal to allocate VND 3.5 billion from the Welfare and Reward Fund for 2024 to be submitted to the General Meeting of Shareholders 2024.

Article VI. Establish the Department of Professional Communications at Tam Duc Cardiology hospital:

The Board of Directors VI.24 unanimously approved the establishment of the Department of Professional Communications under Tam Duc Cardiology hospital joint stock company according to the direction from Dr. Phan Kim Phuong, MD, M.A. - Member of the Board of Directors.

Article VII. Buying ambulances:

The Board of Directors VI.24 unanimously decided to buy 01 Toyota Hiace ambulance with a value of VND 1.4 billion.

Article VIII. Buying HFNC high-flow oxygen ventilator:

The Board of Directors of VI. 24 unanimously decided to buy 2 HFNC high-flow oxygen ventilators with a price of VND 140 million each.

Article IX. Plan orientation for 2024:

Regarding human resources: Tam Duc Cardiology hospital joint stock company has been operating stably and developing for 18 years. Tam Duc's leadership and professional team have matured, but it is necessary to continue recruiting and training post-graduates in key technical positions such as resuscitation, interventional cardiology, and preparing the next generation of leaders.

Regarding expertise: In 2024, outpatient, emergency, and inpatient services are expected to increase by 5% compared to 2023. The number of cardiac surgeries must exceed 400, and the number of interventional cardiology and electrophysiology procedures must exceed 2,000.

Regarding finance:

|  |  |
| --- | --- |
| Total revenue: | VND 700 billion |
| Profit before tax | VND 90 billion. |
| Profit after tax | VND 82 billion |
| Dividend | 33%/par value |

The Board of Directors of VI.24 approved the budget expenditures in 2024 for human resources, professional development, and financial planning.

Article X. The General Meeting of Shareholders 2024:

The General Meeting of Shareholders 2024 will be held on April 27, 2024 at 08:00 a.m. at the Huu Nghi Hall of Tam Duc Cardiology Hospital.

Record date: March 27, 2024

Date to send the notice to convene the General Meeting of Shareholders and meeting documents: April 3, 2024

Contents to be submitted to the General Meeting of Shareholders 2024 for approval:

1. Approve the Performance Report in 2023
2. Approve the Report of the Supervisory Board in 2023
3. Approve the profit distribution plan in 2023. The dividend payment rate in 2023 submitted to the General Meeting of Shareholders for approval is 33% instead of 30% as decided by the General Meeting of Shareholders on April 28, 2023.
4. Approve the proposal to authorize the Board of Directors to select an audit company for the Financial Statements 2024
5. Approve the Business operational plan 2024
6. Approve the Fund appropriation plan for 2024
7. Approve the Dividend payment plan for 2024
8. Elect the Board of Directors in term VII 2024-2028
9. Approve the investment plan for coronary angiography and intervention system No. 4 with a cost of around VND 20 billion with configuration suitable to professional requirements in Q4/2024, the method will be decided by the Board of Directors.
10. Other contents under the authorities of the General Meeting of Shareholders

The Board of Directors VI.24 agrees on the order to convene the General Meeting of Shareholders 2024 on April 27, 2024, the record date to record the list of shareholders is on March 27, 2024 and 10 contents to submit to the General Meeting of Shareholders 2024 for approval.